Longaeva Partners
SION icon

Longaeva Partners’s Sionna Therapeutics SION Stock Holding History

Longaeva Partners’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.64M Buy
196,352
+183,659
+1,447% +$7.35M 0.19% 121
2026
Q1 		$509K Sell
12,693
-67,036
-84% -$2.56M 0.02% 185
2025
Q4 		$3.28M Buy
79,729
+18,272
+30% +$693K 0.28% 81
2025
Q3 		$1.81M Buy
+61,457
New +$1.34M 0.26% 53

Other funds holding SION

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TPG GP A
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Longaeva Partners's SION Position: Q2 2026 in Review

Longaeva Partners increased its Sionna Therapeutics (SION) stake by 1,447% in Q2 2026, buying an estimated $7.35M and bringing the position to 196,352 shares worth $8.64M. The position accounts for 0.19% of the portfolio, ranked #121.

Longaeva Partners first reported a position in SION in Q3 2025 and has held it in 4 quarters since. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Longaeva Partners held 196,352 shares of Sionna Therapeutics worth $8.64M as of Q2 2026.
  • Longaeva Partners bought 183,659 Sionna Therapeutics shares in Q2 2026, an estimated $7.35M.
  • Sionna Therapeutics made up 0.19% of Longaeva Partners's portfolio in Q2 2026, its #121 holding.
  • Longaeva Partners first reported a position in Sionna Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.